Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1464194

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

Description:
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, Q4 2010”, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). “Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Genzyme Corporation
Abbott Laboratories
United Therapeutics Corporation
Ash Access Technology, Inc.
Amgen Inc.
Eli Lilly and Company
Rockwell Medical Technologies, Inc.
Novartis AG
Astellas Pharma Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Cyclacel Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc.
Dynavax Technologies Corporation
ProMetic Life Sciences Inc.
AplaGen GmbH
Proteon Therapeutics, Inc.
Reata Pharmaceuticals, Inc.
Thrasos, Inc.
Concert Pharmaceuticals, Inc.
CorMedix, Inc.
Vitae Pharmaceuticals, Inc.
Relypsa, Inc.
Endacea, Inc.
Vifor Pharma Ltd.
Sorbent Therapeutics, Inc.
InVasc Therapeutics, Inc.
Eurofarma
Varinel, Inc.
Iperboreal Pharma srl
Universities/Institutes Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AMG 223 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CellCept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferinject - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genz-644470 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HEPLISAV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-146 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SBR759 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulodexide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YM533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zemplar (Abbott) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zuragen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
ACE Inhibition - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benazepril + Valsartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bisphosphonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cholecalciferol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dextromethorphan + Silymarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folate + Pyridoxine + Cyanocobalamin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hematide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Irbesartan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iron-Sucrose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicobion + Cinacalcet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renagel + Cinacalcet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosiglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Kidney Disease (Chronic Renal Failure) - Featured News
Nov 22, 2010: Reata And Abbott Announce Positive Phase IIb Chronic Kidney Disease Study Results For Bardoxolone Methyl
Nov 19, 2010: FibroGen To Present Phase IIa Results Of FG-4592 At American Society Of Nephrology Renal Week
Nov 11, 2010: Reata Pharmaceuticals To Present Data From Pivotal Phase IIb Trial In Type 2 Diabetics With Chronic Kidney Disease
Oct 25, 2010: Tengion Presents New Animal Data On Kidney Regeneration At American Society For Transplantation Annual Conference
Oct 18, 2010: Amgen To Review TREAT Results And Propose Updates To ESA Labeling For Chronic Renal Failure Patients At FDA Advisory Committee Meeting
Sep 29, 2010: Tengion Presents Data On Neo-Kidney Augment At International Society For Cellular Therapy
Sep 28, 2010: Dynavax Announces DSMB Clearance To Continue Two Phase III HEPLISAV Trials In CKD Patients
Sep 13, 2010: Tengion Announces Publication Of Preclinical Study In American Journal Of Physiology Renal Physiology
Jun 29, 2010: Vifor Pharma's PA21 Meets Primary And Secondary Endpoints In Phase II Study
Jun 25, 2010: CorMedix Initiates Phase II Clinical Trial Of CRMD-001 For Treatment Of Chronic Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1464194

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Nov 29, 2014
12:37:41 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1464194

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Nov 29, 2014
12:37:41 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)